TenX Keane Acquisition Ordinary Share
TENK
NASDAQ40.50
USD
+3.00
- -
CIK
0001851484
ISIN
KYG8708L1041
Return %
Stock
S&P500
1Y
277.80
18.21
3Y
301.39
63.29
5Y
301.39
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiaofeng Yuan
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 500 Fifth Avenue New York City NY United States of America 10110
- IPO Date
- Dec 8, 2022
- CIK
- 0001851484
- Website
- tenxkeane.com
- Similar Companies
- Business
- TenX Keane Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in 2021 and based in New York, New York. The company was formed primarily for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a strategic focus on target businesses operating in Asia, excluding mainland China, Hong Kong, and Macau. TenX Keane Acquisition does not have significant operations of its own. In August 2024, TenX Keane Acquisition completed a reverse merger with Citius Pharmaceuticals' wholly owned oncology subsidiary, resulting in the formation of Citius Oncology, Inc., a publicly traded company listed on the Nasdaq stock exchange. As part of this transaction, TenX Keane Acquisition acquired the oncology subsidiary, and the newly combined company operates under the Citius Oncology name. Citius Pharmaceuticals retains approximately 90% majority ownership of Citius Oncology, enabling greater financial and strategic flexibility to advance its late-stage oncology assets. Citius Oncology focuses on the development and commercialization of oncology products and services, including the recently FDA-approved LYMPHIR, a treatment for rare lymphoma. The company also explores additional potential oncology assets to expand its pipeline. The merger supports the commercialization of LYMPHIR and provides improved access to public equity markets to facilitate growth initiatives. Citius Pharmaceuticals continues to develop other assets, such as the Mino-Lok antibiotic lock solution targeting a substantial market. Thus, TenX Keane Acquisition's latest major change is its merger and rebranding as Citius Oncology, Inc., transitioning from a blank-check SPAC to an operational oncology company with a robust product pipeline and public market presence, headquartered in New Jersey with significant operations in the United States and focus on global oncology markets excluding certain Asian regions. This strategic transition was completed to enhance the oncology subsidiary's market positioning and financial resources for product development and commercialization. TenX Keane Acquisition’s business transformation reflects a shift from a shell acquisition company to an active pharmaceutical entity specializing in oncology after the 2024 merger with Citius Pharmaceuticals' oncology subsidiary.